# Commission Regulation (EU) No 866/2014 of 8 August 2014 amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on cosmetic products (Text with EEA relevance)

# COMMISSION REGULATION (EU) No 866/2014

# of 8 August 2014

# amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on cosmetic products

# (Text with EEA relevance)

### THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products<sup>(1)</sup>, and in particular Article 31(2) thereof,

Whereas:

- (1) The substances identified by the denominations alkyl ( $C_{12-22}$ ) trimethyl ammonium bromide and chloride are regulated as preservatives under entry 44 of Annex V to Regulation (EC) No 1223/2009 with a maximum concentration of 0,1 %.
- (2) The Scientific Committee on Consumer Products ('SCCP'), subsequently replaced by the Scientific Committee on Consumer Safety ('SCCS') pursuant to Commission Decision  $2008/721/\text{EC}^{(2)}$ , evaluated the safety of alkyl (C<sub>16</sub>, C<sub>18</sub>, C<sub>22</sub>) trimethylammonium chloride (cetrimonium chloride, steartrimonium chloride and behentrimonium chloride) for other uses than as preservatives in 2005, 2007 and 2009.
- (3) The SCCS concluded in its opinion of 8 December 2009<sup>(3)</sup> that, apart from the fact that quaternary ammonium derivative formulations have the potential to be skin irritants, especially when combinations of the concerned compounds are used, the use of cetrimonium chloride, steartrimonium chloride and behentrimonium chloride does not pose a risk to the health of the consumer in concentrations below certain limits, which are explicitly set out in the SCCS opinion.
- (4) In order to take into account the skin irritation potential of the combinations of the quaternary ammonium derivatives mentioned above, the Commission considers that, while allowing the use of these substances for other uses than as preservatives at higher concentrations, the sums of these substances should be restricted to the maximum concentration indicated by the SCCS for the individual substances.
- (5) The maximum concentrations indicated by the SCCS as safe for leave-on facial cream products should apply to all leave-on face products, as there is no reason to limit authorisation of those substances to leave-on face creams only.

- (6) New entries in Annex III to Regulation (EC) No 1223/2009 should therefore be added to reflect the above-mentioned considerations, and entry 44 in Annex V should crossrefer to the new entries in Annex III, so that those Annexes are adapted to technical and scientific progress.
- (7) The SCCS evaluated the safety of the mixture citric acid (and) silver citrate. In its opinion of 13 October 2009<sup>(4)</sup>, it stated that, on the basis of the data submitted, the use of that mixture as a preservative in cosmetic products, at a concentration up to 0,2 % (corresponding to a silver concentration of 0,0024 %), does not pose a risk to the health of the consumer. The Committee specified that the substance was safe when used at the same maximum concentration in deodorants and anti-perspirants, as a preservative and/or an active ingredient. Its use in oral and eye products was, however, explicitly excluded given that only dermal exposure was assessed.
- (8) A new entry in Annex V to Regulation (EC) No 1223/2009 should be added to reflect the above-mentioned considerations and to adapt it to technical and scientific progress.
- (9) The SCCS assessed tris-biphenyl triazine, which is a UV-filter and a nanomaterial. In its opinion of 20 September 2011<sup>(5)</sup>, it concluded that dermal exposure to formulations containing tris-biphenyl triazine with a mean particle size (median primary particle size) of 81 nm results in low absorption of that substance. Also after oral exposure, absorption of tris-biphenyl triazine is low. No systemic effects are observed after oral or dermal exposure up to 500 mg/kg bw/day. The data analysed by the SCCS leads to the conclusion that the use of 10 % tris-biphenyl triazine, including as nanomaterial, as a UV-filter in cosmetic products can be considered safe for dermal application.
- (10) However, the SCCS clarified that, at the time of the risk assessment, there was too much uncertainty to conclude about safe use of 10 % tris-biphenyl triazine in spray applications, because of concerns over possible inhalation exposure. Therefore, the SCCS concluded that spray products containing tris-biphenyl triazine cannot be recommended until additional information on safety after repeated inhalation is provided.
- (11) In light of the SCCS opinion and taking into account that the use of nanomaterials can improve the efficiency of UV-filters, Annex VI to Regulation (EC) No 1223/2009 should be amended for the purpose of adapting it to technical and scientific progress.
- (12) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Cosmetic Products,

HAS ADOPTED THIS REGULATION:

#### Article 1

Annexes III, V and VI to Regulation (EC) No 1223/2009 are amended in accordance with the Annex to this Regulation.

#### Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

# [<sup>X1</sup>ANNEX

#### **Editorial Information**

X1 Substituted by Corrigendum to Commission Regulation (EU) No 866/2014 of 8 August 2014 amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on cosmetic products (Official Journal of the European Union L 238 of 9 August 2014).

Annexes III, V and VI to Regulation (EC) No 1223/2009 are amended as follows:

(1) In Annex III, the following entries 286 and 287 are added:

		nce Ident	ification	Conditions				Wording
Referen	cEhemic	aName	CAS EC		Product Maximuther			
number	• name/	of	numbe	r numbe	r type,	concent	ration	of
	INN	Comme	on		Body	in		condition
		Ingredi	ents		parts	ready		of use
		Glossar	у			for		and
						use		warnings
						prepara		
a	b	c	d	e	f	g	h	i
<b>'</b> 286	C <sub>16</sub> -	Cetrimo	nilulu2-02-7	203-928	6	ית	For	
		rethlylade	honium		(a)	(Rai)nse- off hair products	2 purposes	
	chloride						other	
	C <sub>18</sub> -	Steartrin	447163 \$	203-929	1		than	
	alkyltrin			0205-727	1		the individu	g al
	chloride	remyiano	nonnunn					
	cinoriae						aeveropti	nentis
							8f theoro-	
							organism	15
							the product. muvidu	al
							fancentr	ations
							flas	
							cetrimor	ium
							splaride	
						and		
							steartrim	
							sheseida	ion
							of the	
					(b)	(be)ave-	product.	
						on	⁰∕₀	
						hair	for	
						products		
							individu	
							concentr	ations
							or	
							the	

**a** For use as a preservative, see Annex V, entry No 44.'

						sum of the individual concentrations of cetrimonium chloride and steartrimonium chloride
				(c)	(a)ave- on face products	0,5 % for the individual concentrations or the sum of the individual concentrations of cetrimonium chloride and steartrimonium
287	C <sub>22</sub> - alkyltrim chloride	Behentri	32041-327-	-0 (a)		For purposes other than thibiting individual deverstration of heber trimonium of galidsms fif the product. TWD purpose has individual apparentiations fifom of primonium of plessifiation

							otetherim	onium
							phodricte	
							and	
							behentrin chloride.	
							while	
							at	
							the	
							same	
							time	
							respectir	g
							the	
							relevant	
							maximu	
							concentr for	ation
							the	
							sum	
							of	
							cetrimor	ium
							chloride	
							and	
							steartrim	onium
							chloride set	
							out	
							in	
							entry	
							286.	
					(b)	(be)ave-	3,0	
					, ,	on	%	
						hair	for	
						products		1
							individu	
							concentr of	ation
							behentri	nonium
							chloride	
							or	
							the	
							sum	
							of	
							the individua	-1
							concentr	
							of	anons
							cetrimon	ium
							chloride.	
							steartrim	
							chloride	
For us	e as a preserv	ative, see Ar	nex V. entry	No 44.'				

**a** For use as a preservative, see Annex V, entry No 44.'

a

Status: Point in time view as at 31/01/2020. Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) No 866/2014. (See end of Document for details)

I	1			1	I	and	
						and behentrin	nonium
						chloride.	
						while	
						at	
						the	
						same	
						time	
						respectir	Ig
						the	0
						relevant	
						maximu	
						concentr	ation
						for	
						the	
						sum of	
						cetrimor	ium
						chloride	
						and	
						steartrim	onium
						chloride	
						set	
						out	
						in	
						entry	
						286.	
				(a)	Interne	2.0	
				(c)	(ce)ave- on	3,0 %	
					face	for	
					products		
					p10 4400	individu	al
						concentr	
						of	
						behentri	monium
						chloride	
						or	
						the	
						sum of	
						the	
						individu	al
						concentr	
						of	
						cetrimon	ium
						chloride,	
						steartrim	onium
						chloride	
						and	
						behentrin	monium
-		nnex V, entry		1			

Status: Point in time view as at 31/01/2020.
Changes to legislation: There are currently no known outstanding effects for the
Commission Regulation (EU) No 866/2014. (See end of Document for details)

						chloride,	
						while	
						at	
						the	
						same	
						time	
						respectin	g
						the	
						relevant	
						maximun	n
						concentra	ation
						for	
						the	
						sum	
						of	
						cetrimon	ium
						chloride	
						and	
						steartrim	onium
						chloride	
						set	
						out	
						in	
						entry	
						286.	
For use	as a preserv	vative, see Ar	nnex V, entry	No 44.'	 		


Annex V is amended as follows:

a

(2)

(a) entry 44 is replaced by the following:

	Substa	nce Ide	ntificati	on	Condi	tions		
	n <b>C</b> ehemic <b>N</b> ame ername/ of INN Comm Ingred Glossa		numbernumbe on lients			ctMaximunther concentration in ready for use preparation		Wording of conditions of use and warnings
a	b	c	d	e	f	g	h	i
ʻ44	(C <sub>12-22</sub> ) trimethy ammon bromide and	chloride cetrimo bromide	ะ <sup>*</sup> , rfiนิศปิ9-( ะ, nliนชิ+02-	<b>5240,</b> -32 ),200-31 72,03-92	1-3,	0,1 %		
		laurtrim bromide		1 <del>2</del> 11,4-290	)-3,			
	se other that	-		e Annex III,				



**b** For use other than as a preservative, see Annex III, No 286.'

(b) entry 59 is added:

a

	Substa	nce Ide	ntificati	on	Condi			
	Referen <b>C</b> ehemic <b>A</b> ame numbername/ of		CAS EC numbernumbe		ProductMaximuther ertype, concentration			Wording of
	INN	Comm			Body	in		conditions
		Ingred			parts	ready		of
		Glossa	ry			for		use
						use		and
						prepa		warnings
a	b	c	d	e	f	g	h	i
<b>'</b> 59	1,2,3-	Citric	—	460-890	)-5	0,2 %,	Not	
	Propane	e <b>tricd</b> rbo	xylic			corresp	otodbæg	
	acid,	(and)				to	used	
	2-	Silver				0,0024	in oral	
	hydroxy					% of	product	S
	monohy	drate				silver	and	
	and						eye	
	1,2,3-						product	s'
	·	etricarbo	xylic					
	acid,							
	2-							
	hydroxy							
	silver(1	+)						
	salt,	- 1						
	monohy	arate						

(3) In Annex VI entry 29 is added:

	Substar	nce Ident	ification		Conditi			
Referen number	cChemic • name/ INN	aName of Commo Ingredi Glossar	on ents	EC • number		t Maxim concent in ready for use prepara	tration	Wording of conditions of use and warnings
a	b	c	d	e	f	g	h	i
ʻ29	1,3,5- Triazine, 2,4,6-	Tris- biphenyl triazine	31274-5	1-8		10 %	Not to be	]

tris[1,1'-				used in	
	]b <b>i</b> phenyl			sprays.	
yl-,	triazine			Only	
including	g(nano)			nanomat	erials
as				having	
nanomat	erial			the	
				followin	g
				character	ristics
				are	
				allowed:	
				—	median
					primary
					particle
					size
					> 80
					nm;
				—	Purity
					≥ 98
					%;
				—	Uncoated'

- (1) OJ L 342, 22.12.2009, p. 59.
- (**2**) OJ L 241, 10.9.2008, p. 21.
- (3) SCCS/1246/09, http://ec.europa.eu/health/scientific\_committees/consumer\_safety/docs/
- (4) SCCS/1274/09, http://ec.europa.eu/health/scientific\_committees/consumer\_safety/docs/ sccs\_o\_004.pdf
- (5) SCCS/1429/11, Revision of 13/14 December 2011, http://ec.europa.eu/health/ scientific\_committees/consumer\_safety/docs/sccs\_o\_070.pdf

# Status:

Point in time view as at 31/01/2020.

#### Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EU) No 866/2014.